Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
VIR

VIR - Vir Biotechnology Inc Stock Price, Fair Value and News

9.74USD-0.62 (-5.98%)Market Closed

Market Summary

VIR
USD9.74-0.62
Market Closed
-5.98%

VIR Alerts

  • Big fall in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

VIR Stock Price

View Fullscreen

VIR RSI Chart

VIR Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-2.46

Price/Sales (Trailing)

16.65

EV/EBITDA

-2.19

Price/Free Cashflow

-1.7

VIR Price/Sales (Trailing)

VIR Profitability

Operating Margin

98.85%

EBT Margin

-690.97%

Return on Equity

-34.86%

Return on Assets

-30.07%

Free Cashflow Yield

-58.78%

VIR Fundamentals

VIR Revenue

Revenue (TTM)

79.6M

Rev. Growth (Yr)

-10.45%

Rev. Growth (Qtr)

235.83%

VIR Earnings

Earnings (TTM)

-539.4M

Earnings Growth (Yr)

53.69%

Earnings Growth (Qtr)

43.71%

Breaking Down VIR Revenue

Last 7 days

-13.3%

Last 30 days

-2.8%

Last 90 days

-9.5%

Trailing 12 Months

-62.5%

How does VIR drawdown profile look like?

VIR Financial Health

Current Ratio

12.9

VIR Investor Care

Shares Dilution (1Y)

1.55%

Diluted EPS (TTM)

-4.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202479.6M000
20231.1B490.7M118.8M86.2M
20222.3B2.1B1.9B1.6B
2021331.1M585.9M840.7M1.1B
202010.1M75.1M75.6M76.4M
201911.9M11.7M10.2M8.1M
20184.7M6.7M8.7M10.7M
20170002.7M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Vir Biotechnology Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 12, 2024
de backer marianne
acquired
-
-
53,118
chief executive officer
Jun 12, 2024
de backer marianne
sold
-
-
-53,118
chief executive officer
Jun 11, 2024
ramasastry saira
sold
-43,789
10.9473
-4,000
-
May 30, 2024
napolitano janet
acquired
-
-
8,000
-
May 30, 2024
nelsen robert
acquired
-
-
8,000
-
May 30, 2024
sigal charles elliott
acquired
-
-
8,000
-
May 30, 2024
ramasastry saira
acquired
-
-
8,000
-
May 30, 2024
more robert j
acquired
-
-
8,000
-
May 30, 2024
scangos george a
acquired
-
-
8,000
-
May 30, 2024
hatfield jeffrey s.
acquired
-
-
8,000
-

1–10 of 50

Which funds bought or sold VIR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
new
-
296
296
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
2,000
239,000
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.93
106,117
263,117
0.03%
May 16, 2024
JANE STREET GROUP, LLC
added
37.11
280,708
1,018,170
-%
May 16, 2024
COMERICA BANK
reduced
-8.43
-27,805
329,144
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-4.51
-37,675
943,225
-%
May 16, 2024
Tidal Investments LLC
new
-
352,018
352,018
0.01%
May 15, 2024
GOLDMAN SACHS GROUP INC
added
56.18
3,328,490
9,140,720
-%
May 15, 2024
Schonfeld Strategic Advisors LLC
new
-
226,566
226,566
-%
May 15, 2024
Royal Bank of Canada
reduced
-80.54
-228,000
55,000
-%

1–10 of 44

Are Funds Buying or Selling VIR?

Are funds buying VIR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VIR
No. of Funds

Unveiling Vir Biotechnology Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
sb investment advisers (uk) ltd
12.4%
16,684,041
SC 13G/A
Feb 13, 2024
vanguard group inc
9.14%
12,297,139
SC 13G/A
Jan 24, 2024
state street corp
5.14%
6,912,082
SC 13G
Jan 23, 2024
blackrock inc.
12.5%
16,864,579
SC 13G/A
Feb 14, 2023
softbank vision fund (aiv m1) l.p.
15.2%
20,259,535
SC 13G/A
Feb 09, 2023
vanguard group inc
7.58%
10,094,501
SC 13G/A
Jan 24, 2023
blackrock inc.
10.6%
14,136,628
SC 13G/A
Sep 13, 2022
arch venture fund ix, l.p.
9.7%
12,916,663
SC 13D/A
Sep 08, 2022
blackrock inc.
10.1%
13,384,194
SC 13G
May 10, 2022
arch venture fund ix, l.p.
14.5%
18,916,663
SC 13D/A

Recent SEC filings of Vir Biotechnology Inc

View All Filings
Date Filed Form Type Document
Jun 12, 2024
4
Insider Trading
Jun 12, 2024
4
Insider Trading
Jun 11, 2024
144
Notice of Insider Sale Intent
Jun 07, 2024
144
Notice of Insider Sale Intent
Jun 05, 2024
8-K
Current Report
Jun 03, 2024
3
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading

Peers (Alternatives to Vir Biotechnology Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Vir Biotechnology Inc News

Latest updates
Defense World24 hours ago
Defense World12 Jun 202411:22 am

Vir Biotechnology Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue235.8%56,376,00016,787,0002,639,0003,797,00062,957,00049,410,000374,557,000803,508,0001,232,459,000812,747,000103,616,000177,068,00089,401,0001,734,0001,928,00066,988,0005,718,000980,0001,403,0002,047,0003,661,000
Cost Of Revenue-92.6%59,000798,00038,00022,0001,907,0005,996,00022,253,00027,921,00090,149,00056,881,0007,836,0001,144,000---------
Costs and Expenses-12.4%136,457,000155,803,000189,371,000218,983,000206,328,000199,912,000179,593,000184,593,000218,631,000240,999,000157,001,000116,051,000160,609,000--------
Operating Expenses-----------157,001,000116,051,000160,609,000110,138,00089,543,00096,039,00077,628,00064,739,00049,083,00037,817,00034,431,000
  S&GA Expenses-15.8%36,273,00043,090,00041,080,00047,101,00046,778,00038,743,00043,174,00041,590,00038,255,00055,777,00050,496,00028,781,00025,739,00023,043,00018,859,00016,386,00012,649,00011,808,0009,220,0008,011,0008,559,000
  R&D Expenses-10.5%100,125,000111,915,000148,253,000171,860,000157,643,000155,173,000114,166,000115,082,00090,227,000128,341,00098,669,00086,126,000134,870,00087,095,00070,684,00079,653,00064,979,00052,931,50039,863,00029,805,00025,872,000
EBITDA Margin5.4%-6.69-7.07-5.41-0.53-0.290.470.790.650.710.51-0.11-0.50---------
Income Taxes105.8%276,000-4,784,000-3,213,000-2,848,000-2,232,000-50,035,00042,420,000-157,228,000403,286,00020,635,000334,00053,000196,000-30,00022,00046,00016,000149,000-13,00019,000-
Earnings Before Taxes46.2%-65,000,000-120,757,000-166,626,000-197,623,000-143,188,000-151,638,000217,732,000-233,721,000921,907,000545,889,000110,762,00061,866,000-168,715,000-105,679,000-84,587,000-31,121,000-77,224,000-63,622,500-48,327,000-33,909,000-28,670,000
EBT Margin5.2%-6.91-7.29-5.55-0.56-0.300.470.780.640.710.50-0.12-0.51---------
Net Income43.7%-65,276,000-115,973,000-163,413,000-194,775,000-140,956,000-101,603,000175,312,000-76,493,000518,621,000525,254,000110,428,00061,813,000-168,911,000-105,649,000-84,609,000-31,167,000-77,240,000-63,771,000-48,314,000-33,928,000-28,670,000
Net Income Margin5.1%-6.78-7.14-5.06-0.53-0.140.320.620.520.520.48-0.12-0.51---------
Free Cashflow-1.6%-111,262,000-109,462,000-159,543,000-398,704,000-132,649,00022,552,00098,909,000939,538,000534,248,000-5,372,000-111,819,000137,981,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32018Q4
Assets-6.5%1,7941,9192,0452,2442,6662,8022,6962,6192,8871,9541,2101,0581,136919943672477512423192
  Current Assets-23.6%1,2131,5881,7691,9462,3592,5192,4142,2882,5681,5631,066862993772850579378403338118
    Cash Equivalents-33.5%1612424526678258689641,50581234871574252145146337216812394.0059.00
  Net PPE-3.7%92.0096.0099.0010410410610085.0066.0043.0027.0020.0017.0018.0017.0016.0016.0016.0015.0012.00
  Goodwill0%17.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.00
Liabilities-25.0%24732937043469572454666788652233432048520213110897.0088.0067.0062.00
  Current Liabilities-46.4%94.0017516522648551130847870234123414636199.0077.0055.0056.0059.0044.0040.00
Shareholder's Equity-2.7%1,5471,5901,6751,8101,9712,0782,1501,9522,0011,432876737651717812564380424--
  Retained Earnings-27.4%-303-237-12142.00236377479304380-138-663774-836-667-561-476-445-368-304-193
  Additional Paid-In Capital1.3%1,8531,8291,7991,7721,7381,7101,6831,6561,6261,5721,5411,5131,4881,3851,3741,04182679324.0015.00
Shares Outstanding0.8%136135134134134133133132132130131129--------
Minority Interest-----0.00---------------
Float----1,800---2,000---2,700---2,300----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-1.4%-109,390-107,927-155,829-389,247-125,78235,126117,902960,136550,0897,695-105,813140,058-89,529-82,052-49,841-10,639-48,409-38,885-36,955-24,303-29,489
  Share Based Compensation-16.0%23,75728,27226,94430,61925,48124,86524,81427,09925,30424,37122,94420,99815,47110,3018,5825,7502,9672,6792,1881,3992,453
Cashflow From Investing127.1%28,420-104,811-58,954230,31598,079-153,135-662,605-272,329-105,392-377,58273,85975,37587,53460,713-185,37910,585104,219-73,76947,29244,483-274,164
Cashflow From Financing-91.0%1521,6802773,1792,3442,0111,9853,08027,6855,6703,6293,52987,503-259324,308205,34085.00130,1001,7323.00317,409
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

VIR Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 56,376$ 62,957
Operating expenses:  
Cost of revenue591,907
Research and development100,125157,643
Selling, general and administrative36,27346,778
Total operating expenses136,457206,328
Loss from operations(80,081)(143,371)
Other income:  
Change in fair value of equity investments(5,915)(13,103)
Interest income21,28321,307
Other expense, net(287)(8,021)
Total other income15,081183
Loss before (provision for) benefit from income taxes(65,000)(143,188)
(Provision for) benefit from income taxes(276)2,232
Net loss(65,276)(140,956)
Net loss attributable to noncontrolling interest0(56)
Net loss attributable to Vir$ (65,276)$ (140,900)
Net loss per share attributable to Vir, basic (in USD per share)$ (0.48)$ (1.06)
Net loss per share attributable to Vir, diluted (in USD per share)$ (0.48)$ (1.06)
Weighted-average shares outstanding, basic (in shares)135,280,648133,552,839
Weighted-average share outstanding, diluted (in shares)135,280,648133,552,839
Collaboration revenue  
Revenues:  
Total revenues$ (987)$ 46,574
Contract revenue  
Revenues:  
Total revenues52,191138
Grant revenue  
Revenues:  
Total revenues$ 5,172$ 16,245

VIR Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
CURRENT ASSETS:  
Cash and cash equivalents$ 160,711$ 241,576
Short-term investments985,1251,270,980
Restricted cash and cash equivalents, current13,33513,268
Equity investments3,9279,853
Prepaid expenses and other current assets49,99952,549
Total current assets1,213,0971,588,226
Intangible assets, net22,46522,565
Goodwill16,93716,937
Property and equipment, net92,47796,018
Operating lease right-of-use assets70,34671,182
Restricted cash and cash equivalents, noncurrent6,4286,448
Long-term investments359,724105,275
Other assets12,49512,409
TOTAL ASSETS1,793,9691,919,060
CURRENT LIABILITIES:  
Accounts payable7,1146,334
Accrued and other liabilities72,260104,220
Deferred revenue, current14,69464,853
Total current liabilities94,068175,407
Deferred revenue, noncurrent1,5261,526
Operating lease liabilities, noncurrent109,171111,673
Contingent consideration, noncurrent27,61025,960
Other long-term liabilities14,23814,258
TOTAL LIABILITIES246,613328,824
Commitments and contingencies (Note 8)
STOCKHOLDERS’ EQUITY:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 202300
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 135,843,560 and 134,781,286 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively1413
Additional paid-in capital1,852,8391,828,862
Accumulated other comprehensive loss(2,397)(815)
Accumulated deficit(303,100)(237,824)
TOTAL STOCKHOLDERS’ EQUITY1,547,3561,590,236
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 1,793,969$ 1,919,060
VIR
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.
 CEO
 WEBSITEvir.bio
 INDUSTRYBiotechnology
 EMPLOYEES576

Vir Biotechnology Inc Frequently Asked Questions


What is the ticker symbol for Vir Biotechnology Inc? What does VIR stand for in stocks?

VIR is the stock ticker symbol of Vir Biotechnology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vir Biotechnology Inc (VIR)?

As of Fri Jun 14 2024, market cap of Vir Biotechnology Inc is 1.33 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VIR stock?

You can check VIR's fair value in chart for subscribers.

What is the fair value of VIR stock?

You can check VIR's fair value in chart for subscribers. The fair value of Vir Biotechnology Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vir Biotechnology Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VIR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vir Biotechnology Inc a good stock to buy?

The fair value guage provides a quick view whether VIR is over valued or under valued. Whether Vir Biotechnology Inc is cheap or expensive depends on the assumptions which impact Vir Biotechnology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VIR.

What is Vir Biotechnology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, VIR's PE ratio (Price to Earnings) is -2.46 and Price to Sales (PS) ratio is 16.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VIR PE ratio will change depending on the future growth rate expectations of investors.